Nevirapine can kills HIV virus

Nevirapine is a white or off-white crystalline powder, also marketed under the trade name Viramune. It is a non-nucleoside reverse transcriptase inhibitor used to treat HIV-1 infection and AIDS. The Molecular Formula of Nevirapine is C15H14N4O, Molecular Weight is 266.3 and CAS Registry Number is 129618-40-2.

Nevirapine was discovered by Hargrave et al. at Boehringer Ingelheim Pharmaceuticals, Inc., one of the Boehringer Ingelheim group of companies. It is covered by U.S. Patent 5,366,972 and corresponding foreign patents. Nevirapine was the first NNRTI approved by the U.S. Food and Drug Administration (FDA). It was approved June 21, 1996 for adults and September 11, 1998 for children. It was also approved in Europe in 1997.

Nevirapine(CAS NO: 129618-40-2) is an oral medication that is used for the treatment of infections with the human immunodeficiency virus (HIV). It is in a class of drugs called reverse transcriptase inhibitors that also includes zalcitabine (Hivid), zidovudine (Retrovir), didanosine (Videx), and lamivudine (Epivir). It is in a subclass of protease inhibitors called nonnucleoside protease inhibitors that includes efavirenz (Sustiva) and delavirdine (Rescriptor). During infection with HIV, the HIV virus multiplies within the body's cells. 

The newly-formed viruses then are released from the cells and spread throughout the body where they infect other cells. In this manner, the infection spreads to new, uninfected cells that the body is continually producing, and HIV infection is perpetuated. When producing new viruses, the HIV virus must manufacture new DNA for each virus. Reverse transcriptase is the enzyme that the virus uses to form this new DNA. 

Nevirapine directly inhibits the activity of reverse transcriptase and blocks the production of DNA and new viruses. Nevirapine does not kill existing HIV virus and it is not a cure for HIV. The FDA approved nevirapine in September 1996.

Longer nevirapine prophylaxis to prevent postnatal HIV infection appears to benefit children, but the gains seem to disappear unless they are treated during the entire breastfeeding period, researchers said here at the Conference on Retroviruses and Opportunistic Infections.

Women were advised to breastfeed the children exclusively through 6 months and then stop, although many continued after 6 months. The median time for cessation of breastfeeding was 6.2 months. We have to treat children with nevirapine prophylaxis as long as they are breastfeeding.

Abrams, who moderated the press briefing at which Fowler discussed the 18-month results of her study, noted, "Women who required treatment were among the women at greatest risk of transmitting virus to their children through breastfeeding. Even if the mother is under treatment, the recommendations are still to deliver nevirapine to the child for 6 weeks.

If you need take Nevirapine, you should pay more attention to it. Learning more health information, properties or suppliers about Nevirapine, you can access Guidechem.